Evonik Evonik

X

Find Camsirubicin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Camsirubicin
Also known as: Vi79rd8vnn, 236095-26-4, Gpx-150, Gpx150, Unii-vi79rd8vnn, Camsirubicin [inn]
Molecular Formula
C27H32N2O9
Molecular Weight
528.5  g/mol
InChI Key
GNCWGPLZJLZZPI-KUIJCEFOSA-N
FDA UNII
VI79RD8VNN

Camsirubicin is a synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Camsirubicin intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis.
1 2D Structure

Camsirubicin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(8R,10S)-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-9,10-dihydro-7H-tetracen-5-one
2.1.2 InChI
InChI=1S/C27H32N2O9/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3/t11-,14-,16-,17-,23+,27-/m0/s1
2.1.3 InChI Key
GNCWGPLZJLZZPI-KUIJCEFOSA-N
2.1.4 Canonical SMILES
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(CCO)O)N)O
2.1.5 Isomeric SMILES
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(CCO)O)N)O
2.2 Other Identifiers
2.2.1 UNII
VI79RD8VNN
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5-imino-13-deoxydoxorubicin

2. Gpx-150

2.3.2 Depositor-Supplied Synonyms

1. Vi79rd8vnn

2. 236095-26-4

3. Gpx-150

4. Gpx150

5. Unii-vi79rd8vnn

6. Camsirubicin [inn]

7. Camsirubicin [who-dd]

8. 5-imino-13-deoxydoxorubicin

9. (8r,10s)-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-5(8h)-naphthacenone

10. (8r,10s)-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxohexopyranosyl) Oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)- 12-imino-1-methoxy-7,9,10,12-tetrahydrotetracen-5(8h)- One

11. 5(8h)-naphthacenone, 10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8r,10s)-

12. 5(8h)-naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8r,10s)-

2.4 Create Date
2019-01-15
3 Chemical and Physical Properties
Molecular Weight 528.5 g/mol
Molecular Formula C27H32N2O9
XLogP31.8
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count11
Rotatable Bond Count5
Exact Mass528.21078060 g/mol
Monoisotopic Mass528.21078060 g/mol
Topological Polar Surface Area196 Ų
Heavy Atom Count38
Formal Charge0
Complexity906
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY